Incyte's Revenue in the fiscal year 2025 $ 5,141.24 millions
Incyte's Revenue in the fiscal year 2024 $ 4,241.22 millions
Incyte's Revenue in the fiscal year 2023 $ 3,695.65 millions
Incyte's Revenue in the fiscal year 2022 $ 3,394.64 millions
Incyte's Revenue in the fiscal year 2021 $ 2,986.27 millions
INCY Revenue first quarter 2026 Y/Y Growth Comment
Incyte Corporation reported Revenue improvement of 20.87% year on year in the first quarter 2026, to $ 1,272.68 millions, this is lower than Incyte Corporation's recent average Revenue improvement of 24.85%.
Looking into first quarter 2026 results within Medical Laboratories industry 6 other companies have achieved higher Revenue growth. While Incyte Corporation' s Revenue rise of 20.87% ranks overall at the positon no. 519 in the first quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Incyte's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
408.95 %
16.7 %
-66.15 %
(Dec 31 2010)
INCY's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Incyte Corporation disclosed fall in Revenue from the fourth quarter by -15.54% to $ 1,272.68 millions, from $ 1,506.84 millions achived in the previous reporting period.
But that's not important problem, as Incyte's Revenue generally seem to plunge in this quarter.
Within Medical Laboratories industry 29 other companies have achieved higher Revenue quarter on quarter growth. While Incyte's Revenue growth quarter on quarter, overall rank is 3108.
In the I. Quarter 2026 Incyte Corporation disclosed fall in Revenue from the fourth quarter by -15.54% to $ 1,272.68 millions, from $ 1,506.84 millions achived in the previous reporting period.
But that's not important problem, as Incyte's Revenue generally seem to plunge in this quarter.
Within Medical Laboratories industry 29 other companies have achieved higher Revenue quarter on quarter growth. While Incyte's Revenue growth quarter on quarter, overall rank is 3108.
Incyte's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
12 Months Ending (Mar 31 2025)
Cumulative Revenue 12 Months Ending
$ 5,361.02
$ 5,141.24
$ 4,813.11
$ 4,585.00
$ 4,413.23
Y / Y Revenue Growth (TTM)
21.48 %
21.22 %
18.09 %
18.87 %
17.13 %
Year on Year Revenue Growth Overall
Ranking
# 154
# 845
# 105
# 1010
# 340
Seqeuential Revenue Change (TTM)
4.27 %
6.82 %
4.98 %
3.89 %
4.06 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2181
# 1764
# 216
# 1776
# 593
Cumulative Revenue growth Comment
Although Incyte's Annual Revenue growth year on year were below company's average 24.85% , Revenue announced in the Mar 31 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 21.48% year on year, from 21.22% in Dec 31 2025.
Within the Healthcare sector 21 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 154, from total ranking in previous quarter at 845.
Although Incyte's Annual Revenue growth year on year were below company's average 24.85% , Revenue announced in the Mar 31 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 21.48% year on year, from 21.22% in Dec 31 2025.
Within the Healthcare sector 21 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 154, from total ranking in previous quarter at 845.
About Incyte Revenue Growth Rates (INCY), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
36.47%